GlassScriptPhysician profile
Christopher L Sperry
NPI 1386870046
$3,812.10
in general payments reported to CMS, 2019-2025
32 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $307 · 2021: $819 · 2022: $609 · 2023: $465 · 2024: $213 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.03 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $372.07 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $333.40 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $246.68 | 2019-2024 | |
| Amgen INC. | $217.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $199.60 | 2019-2022 | |
| Allergan, INC. | $192.19 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $152.03 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.19 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.42 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $127.41 | 2019-2025 | Farxiga |
| Medtronic, INC. | $112.70 | 2023-2025 | Reveal Linq, Inpen Smart Insulin Delivery System, Minimed 780g |
| Exact Sciences Corporation | $98.83 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $82.03 | 2022 | |
| Glaxosmithkline, LLC. | $58.51 | 2023-2024 | Trelegy Ellipta, Bexsero, Rotarix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.96 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.19 | 2024 | Invega Sustenna |
| Dynavax Technologies Corporation | $36.00 | 2025 | Heplisav-B |
| Ironshore Pharmaceuticals INC. | $31.65 | 2019 | |
| Gilead Sciences, INC. | $29.81 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $20.51 | 2025 | |
| Alkermes, INC. | $20.29 | 2024 | Aristada, Lybalvi |
| Phathom Pharmaceuticals, INC. | $19.72 | 2024 | Voquezna |
| Shire North American Group INC | $19.45 | 2019 | |
| Astellas Pharma US INC | $18.92 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $16.58 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $16.49 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.37 | 2025 | NP Thyroid 60 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.99 | 2022 | |
| Tolmar, INC. | $13.91 | 2025 | Jatenzo |
| Genentech USA, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.